The efficacy of Omega-3 fatty acids (Omegaven) for patients with liver disease secondary to intestinal failure

The efficacy of Omega-3 fatty acids (Omegaven) for patients with liver disease secondary to intestinal failure - The efficacy of Omega-3 fatty acids (Omegaven) for patients with liver disease secondary to intestinal failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020159

Enrollment

Registered

2015-12-10

Start date

2016-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intestinal failure associated liver disease

Interventions

Intravenous administration of Omegaven The dose of Omegaven will be initiated from 0.2g/kg/day, and increased step by step up tp 1.0g/kg/day. The Omegaven will be administered via central venous cath

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients suffering from liver disease associated with intestinal failure and serum Direct Bilirubin > 2.

Exclusion criteria

Exclusion criteria: Conditions including severe infections, poorly controlled diabetes, shock, coagulopathy, fat metabolism disorder, allergic to fish or eggs

Design outcomes

Primary

Measure	Time frame
The reduction of direct bilirubin	—

Secondary

Measure	Time frame
Histological analysis of the liver, Acoustic Radiation Force Impulse of the liver, nutritional status	—

Countries

Japan

Contacts

Public ContactYohei Yamada

Keio University School of Medicine Department of Pediatric Surgery

yohei@z7.keio.jp03-5363-3024

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026